Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1

Shira Tabachnick-Cherny1, Thomas Pulliam1, Haroldo J Rodriguez1

  • 1Department of Dermatology, University of Washington, Seattle, Washington.

Abstract

Insights

Tumor-associated macrophages (TAMs) in Merkel cell carcinoma (MCC) may hinder immunotherapy response by suppressing T-cell activity. Targeting these TAMs could improve treatment outcomes for this skin cancer.

Area of Science:

  • Immunology
  • Oncology
  • Dermatology

Background:

  • Merkel cell carcinoma (MCC) is an aggressive skin cancer with variable response to PD-(L)1 blockade.
  • Prior research on MCC immunobiology has focused on T-cells, leaving the role of innate immunity, particularly myeloid cells, underexplored.

Purpose of the Study:

  • To identify myeloid cell populations in MCC tumors.
  • To evaluate the association of myeloid cells with response to immunotherapy.
  • To elucidate potential immunosuppressive mechanisms employed by myeloid cells in MCC.

Main Methods:

  • Single-cell transcriptomics was performed on MCC tumors from 9 patients.
  • Multiplex immunohistochemistry (IHC) staining was conducted on 54 pre-immunotherapy MCC tumors.
  • Analysis focused on identifying myeloid cell subsets and their correlation with clinical outcomes.

Main Results:

  • Tumor-associated macrophages (TAMs) were identified as the dominant myeloid component in MCC, expressing immunosuppressive markers and immune checkpoint molecules (PD-L1, LILRB).
  • Higher TAM prevalence correlated with resistance to PD-1 blockade, particularly in tumors with significant CD8 T-cell infiltration.
  • TAMs exhibited cytokine signaling, suggesting potential immunosuppressive mechanisms that counteract T-cell responses.

Conclusions:

  • TAMs represent a key myeloid component in MCC tumors with a distinct immunosuppressive phenotype.
  • TAMs may reduce the efficacy of immunotherapy in MCC by inhibiting CD8 T-cell anti-tumor activity.
  • Targeting TAMs presents a potential strategy to overcome immunotherapy resistance in Merkel cell carcinoma.